Earnings summaries and quarterly performance for Mirum Pharmaceuticals.
Executive leadership at Mirum Pharmaceuticals.
Board of directors at Mirum Pharmaceuticals.
Research analysts who have asked questions during Mirum Pharmaceuticals earnings calls.
DL
David Lebowitz
Citigroup Inc.
4 questions for MIRM
Also covers: ALNY, ARWR, ASND +11 more
Gavin Clark-Gartner
Evercore ISI
4 questions for MIRM
Also covers: ACRS, ARGX, ASND +11 more
JF
Jessica Fye
JPMorgan Chase & Co.
4 questions for MIRM
Also covers: ALKS, ALNY, AMRN +23 more
Ryan Deschner
Raymond James Financial
4 questions for MIRM
Also covers: APLS, ARDX, ARSP +7 more
JW
Jon Wolleben
Citizen JMP
2 questions for MIRM
Also covers: BCRX, CLSD, MDGL +3 more
MU
Michael Ulz
Morgan Stanley
2 questions for MIRM
Also covers: ALNY, ARWR, FATE +8 more
Ryan Mcelroy
Leerink Partners
2 questions for MIRM
Also covers: BBIO, RGNX
Abdullah
J.P. Morgan
1 question for MIRM
Brian Skorney
Robert W. Baird & Co.
1 question for MIRM
Also covers: ABUS, CRNX, MRNS +6 more
Catherine Okoukoni
Citizens JMP
1 question for MIRM
Also covers: ALT, CRNX, KALV +2 more
DG
Dae Gon Ha
Stifel
1 question for MIRM
Also covers: ABEO, BEAM, CRBP +10 more
GC
Gavin Clark-Gardner
Evercore
1 question for MIRM
JW
Jonathan Wolleben
JMP Securities, a Citizens Company
1 question for MIRM
Also covers: ALT, BCRX, CLSD +5 more
Joseph Thome
TD Cowen
1 question for MIRM
Also covers: ALKS, AMLX, ARDX +12 more
JS
Josh Schimmer
Cantor Fitzgerald
1 question for MIRM
Also covers: BBIO, BYSI, CRNX +3 more
JS
Joshua Schimmer
Evercore ISI
1 question for MIRM
Also covers: KRYS, NBIX, SPRY
M
Mark
Stifel
1 question for MIRM
R
Rohit
Morgan Stanley
1 question for MIRM
Rohit Bhasin
Morgan Stanley
1 question for MIRM
Also covers: GUTS, VKTX
R
Ryan
B. Riley
1 question for MIRM
Also covers: BEEM, PATH, PPG
Selena Zhang
Morgan Stanley
1 question for MIRM
SR
Swayampakula Ramakanth
H.C. Wainwright & Co.
1 question for MIRM
Also covers: ABSI, BSEM, CGEN +24 more
TY
Thomas Yip
H.C. Wainwright & Co.
1 question for MIRM
Also covers: ABUS, ARDX, ENTA +6 more
Timur Ivannikov
Raymond James
1 question for MIRM
Also covers: APLS, GLMD, IFRX
Recent press releases and 8-K filings for MIRM.
Mirum Pharmaceuticals Provides 2026 Guidance and Pipeline Updates at J.P. Morgan Healthcare Conference
MIRM
Guidance Update
New Projects/Investments
M&A
- Mirum Pharmaceuticals reported estimated $520 million in total product revenue for 2025 and issued 2026 guidance of $630-$650 million.
- The company anticipates several key pipeline readouts, including top-line data for the Volixibat VISTAS PSC study in Q2 2026, an interim look at the Brilovatug AZURE 1 program in Q2 2026, and top-line data for the Livmarli EXPAND study in Q4 2026.
- Mirum is progressing with the proposed acquisition of BlueJ Therapeutics, which will add Brilovatug for hepatitis delta, projected to be at least a $750 million opportunity, to its portfolio.
- Livmarli generated $359 million in net product revenue in 2025, with its tablet formulation having IP protection until 2043.
1 day ago
Mirum Pharmaceuticals Reports Strong 2025 Revenue and Provides 2026 Guidance, Highlights Pipeline Catalysts and BlueJay Acquisition
MIRM
Guidance Update
Revenue Acceleration/Inflection
M&A
- Mirum Pharmaceuticals reported an estimated $520 million in total product revenue for 2025 and issued 2026 guidance for total product revenue between $630 million and $650 million.
- The company expects several significant pipeline readouts in 2026, including top-line data for the Volixibat VISTAS PSC study and an interim look at the Brilovatug AZURE 1 program in Q2 2026, followed by top-line data for Brilovatug AZURE 1 and 4 in H2 2026, and the Livmarli EXPAND study in Q4 2026.
- Mirum announced the proposed acquisition of BlueJay Therapeutics, adding Brilovatug for hepatitis delta (HDV) to its portfolio, which is projected to be at least a $750 million opportunity.
- Livmarli, the company's lead product, achieved $359 million in net product revenue in 2025 and has a billion-plus potential opportunity, with average net pricing for Alagille syndrome patients ranging from mid-$400,000 to $500,000 per year.
1 day ago
Mirum Reports Strong 2025 Revenue, Issues 2026 Guidance, and Highlights Key Pipeline Catalysts
MIRM
Guidance Update
M&A
Revenue Acceleration/Inflection
- Mirum announced estimated $520 million in total product revenue for 2025 and provided 2026 guidance of $630-$650 million.
- The company anticipates several key pipeline readouts in the next 18 months, including Volixibat VISTAS PSC study top-line data in Q2 2026, Brilovatug AZURE programs top-line data in H2 2026, and Livmarli EXPAND study data in Q4 2026.
- Mirum is in the process of acquiring BlueJ Therapeutics, adding Brilovatug for hepatitis delta to its portfolio, which is seen as at least a $750 million opportunity.
- The company expects to be cash flow positive in 2027 and projects over $4 billion of potential revenue across its current commercial and pipeline programs.
1 day ago
Mirum Pharmaceuticals Announces Preliminary 2025 Results and 2026 Outlook
MIRM
Earnings
Guidance Update
M&A
- Mirum Pharmaceuticals reported preliminary unaudited 2025 net product sales of approximately $520 million, surpassing the upper end of its guidance, and projects 2026 global net product sales of $630 million to $650 million.
- The company achieved positive cash flow from operations in 2025 and ended the year with approximately $392 million in cash, cash equivalents, and investments as of December 31, 2025.
- Mirum is expanding its pipeline through the proposed acquisition of Bluejay Therapeutics, which will add brelovitug for chronic hepatitis delta virus (HDV), with topline Phase 3 data expected in H2 2026.
- Key clinical milestones anticipated for 2026 include topline data from the Volixibat VISTAS study in primary sclerosing cholangitis (PSC) in Q2 2026 and topline data from the LIVMARLI EXPAND study in additional cholestatic pruritus settings in Q4 2026.
3 days ago
Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results and 2026 Outlook
MIRM
Earnings
Guidance Update
M&A
- Mirum Pharmaceuticals reported preliminary unaudited net product sales of approximately $520 million for 2025, surpassing the upper end of its guidance, with LIVMARLI sales at approximately $359 million and CHOLBAM and CTEXLI sales at approximately $161 million.
- For 2026, the company anticipates global net product sales between $630 million and $650 million.
- Mirum achieved positive cash flow from operations in 2025 and ended the year with an estimated cash, cash equivalents, and investments balance of approximately $392 million as of December 31, 2025.
- The proposed acquisition of Bluejay Therapeutics is expected to close in mid-to-late January 2026, adding brelovitug for chronic hepatitis delta virus (HDV) with topline Phase 3 data expected in H2 2026. Additionally, Volixibat VISTAS study topline data is expected in Q2 2026 and LIVMARLI EXPAND study topline data in Q4 2026.
3 days ago
Mirum Pharmaceuticals Files Patent Infringement Suits Against Generic Drugmakers
MIRM
Legal Proceedings
- Mirum Pharmaceuticals, Inc. received Paragraph IV Certification Notice Letters in November 2025 from Sandoz, Inc., Annora Pharma Private Limited, Zydus Lifesciences Global FZE, and Zenara Pharma Private Limited, indicating their intent to seek approval for generic versions of its drug Livmarli® (maralixibat).
- On December 19, 2025, Mirum filed patent infringement lawsuits against these companies in the United States District Court for the District of Delaware.
- These lawsuits allege infringement of Mirum's Orange Book listed patents for Livmarli® and result in a 30-month stay, preventing the FDA from issuing final approval for the generic Abbreviated New Drug Applications (ANDAs).
Dec 19, 2025, 9:06 PM
Mirum Pharmaceuticals Announces Additional Private Placement Financing
MIRM
M&A
New Projects/Investments
- Mirum Pharmaceuticals entered into a subscription agreement with TCGX for a private placement of 1,000,000 shares of its common stock at $68.48 per share, generating approximately $68.5 million in gross proceeds.
- This financing, combined with a previous $200 million private placement announced earlier this month, is intended to fund clinical development and commercial activities following the proposed acquisition of Bluejay Therapeutics.
- Both private placements are expected to close concurrently with the Bluejay acquisition, which is anticipated in the first quarter of 2026, subject to regulatory approval and other customary closing conditions.
Dec 19, 2025, 1:30 PM
Mirum Pharmaceuticals announces acquisition of BlueJ Therapeutics
MIRM
M&A
New Projects/Investments
Guidance Update
- Mirum Pharmaceuticals has entered into a definitive agreement to acquire BlueJ Therapeutics for $250 million in cash and $370 million in Mirum stock, with up to $200 million in sales-based milestone payments.
- The acquisition adds tegovibart, a late-stage asset for chronic hepatitis delta virus, which has demonstrated 100% virologic response in Phase II studies and holds FDA Breakthrough Therapy designation.
- This transaction is expected to close in the first quarter of 2026 and is projected to increase Mirum's rare disease portfolio revenue potential to over $4 billion.
- Mirum secured $200 million in private placement financing to fund the acquisition and anticipates becoming cash flow positive in 2027.
- Tegovibart's Phase III program is ongoing, with interim data from Azure One expected in Q2 2026 and final data from Azure One and Four in H2 2026, targeting a BLA submission in the first half of 2027.
Dec 8, 2025, 1:30 PM
Mirum Pharmaceuticals to Acquire BlueJ Therapeutics
MIRM
M&A
New Projects/Investments
Revenue Acceleration/Inflection
- Mirum Pharmaceuticals has entered into a definitive agreement to acquire BlueJ Therapeutics for $250 million in cash, $370 million in Mirum stock (priced at $71.21 per share), and up to $200 million in tiered sales-based milestone payments.
- The acquisition adds tegovibart, an anti-hepatitis B surface antigen monoclonal antibody for chronic hepatitis delta virus (HDV), to Mirum's pipeline. Tegovibart has received FDA Breakthrough Therapy and EU PRIME designations based on compelling Phase II results.
- The transaction is expected to close in the first quarter of 2026 and is being funded in part by a concurrent $200 million private placement financing.
- Tegovibart is currently in a Phase III program (Azure studies), with interim data from Azure One expected in Q2 2026 and final data from Azure One and Four expected in the second half of 2026 to support a potential BLA submission in the first half of 2027.
- Mirum anticipates tegovibart has a global revenue potential of at least $750 million, contributing to an overall rare disease portfolio revenue potential of over $4 billion.
Dec 8, 2025, 1:30 PM
Mirum Pharmaceuticals Announces Proposed Acquisition of Bluejay Therapeutics
MIRM
M&A
New Projects/Investments
- Mirum Pharmaceuticals has announced the proposed acquisition of Bluejay Therapeutics, with the transaction expected to close in Q1 2026.
- The acquisition is valued at $250 million in cash and $370 million in stock (issued at $71.21 per share), with potential additional payments of up to $200 million in tiered sales milestones.
- This strategic move is expected to enhance Mirum's position in rare liver disease by integrating Brelovitug, Bluejay's Hepatitis Delta Virus (HDV) treatment, which has an estimated $750 million+ revenue potential.
- Mirum plans to fund the acquisition with a $200 million private placement at $68.48 per share, while maintaining its financial independence.
Dec 8, 2025, 1:30 PM
Quarterly earnings call transcripts for Mirum Pharmaceuticals.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more